Oscillatory potential (OP) analysis of 6-, 9-, and 12-month ERGs shows continued dysfunction in the inner retina reflecting A- and B-wave results. by Shaylah McCool (20818280)

“…<p>(A) Example OP traces from C57 (black) and 5xFAD (blue) mice at 3 timepoints show significantly increased OP amplitudes in the 6-month 5xFAD mice and significantly decreased OP amplitudes in the 9-month 5xFAD mice. …”

Univariate analyses. by Zachary E. M. Giovannini-Green (22008277)

“…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. …”

Overview of individuals in the study. by Zachary E. M. Giovannini-Green (22008277)

“…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. …”

Multivariate analyses. by Zachary E. M. Giovannini-Green (22008277)

“…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. …”

Electroretinogram (ERG) recordings from 6-, 9-, and 12-month mice show deficits in 5xFAD photoreceptors. by Shaylah McCool (20818280)

“…(C) Quantification of A- and B-wave amplitudes at the highest intensity stimulus (3.0000 cd * s/m²) shows the significant increase and decrease in retinal function in the 6- and 9-month 5xFAD mice, respectively, analyzed by two-way ANOVA with Tukey’s multiple comparisons. …”

Changes in blood pressure, HbA1c, blood lipid and liver function-related indicator values compared with baseline values in all patients over time. by Jia Song (495396)

Effects of warming and nitrogen deposition on plant species diversity. Different lowercase letters indicated that there were significant differences in different nitrogen depositio... by Xuemei Xiang (20756894)

Subjects:

NeuN staining of 6-, 9-, and 12-month dLGN sections shows loss of thalamocortical cell bodies in the 5xFAD mice. by Shaylah McCool (20818280)

Table 3_Association between platelet-to-red cell distribution width ratio and all-cause mortality in critically ill patients with non-traumatic cerebral hemorrhage: a retrospective... by Rongrong Lu (322302)

“…As PRR increased, restrictive cubic splines showed a progressive decrease in the probability of all-cause mortality. …”

Table 1_Association between platelet-to-red cell distribution width ratio and all-cause mortality in critically ill patients with non-traumatic cerebral hemorrhage: a retrospective... by Rongrong Lu (322302)

“…As PRR increased, restrictive cubic splines showed a progressive decrease in the probability of all-cause mortality. …”

Table 2_Association between platelet-to-red cell distribution width ratio and all-cause mortality in critically ill patients with non-traumatic cerebral hemorrhage: a retrospective... by Rongrong Lu (322302)

“…As PRR increased, restrictive cubic splines showed a progressive decrease in the probability of all-cause mortality. …”

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

The catalase enzyme response of <i>A</i>. <i>albopictus</i> larvae decreased (1.5-fold) in response to <i>M</i>. <i>robertsii</i>-derived copper nanoparticles. by Perumal Vivekanandhan (4863484)

Subjects:

The effect of feeding and starvation on the proliferative competence and onset of cell cycle re-entry in all cell cycle-gated cells. by Eudald Pascual-Carreras (12115380)

Forest plots of APTT for 28-day mortality in different subgroups. by Huan Wang (109286)

Subjects:

Baseline characteristics and potential independent risk factors for mortality of SFTS. by Huan Wang (109286)

Subjects: